These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33191280)

  • 21. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.
    Helliwell PS; Gladman DD; Chakravarty SD; Kafka S; Karyekar CS; You Y; Campbell K; Sweet K; Kavanaugh A; Gensler LS
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32209721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial.
    Gladman DD; Bombardier C; Thorne C; Haraoui B; Khraishi M; Rahman P; Bensen W; Syrotuik J; Poulin-Costello M
    J Rheumatol; 2011 Jul; 38(7):1355-62. PubMed ID: 21572156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.
    Harrold LR; Stolshek BS; Rebello S; Collier DH; Mutebi A; Wade SW; Malley W; Greenberg JD; Etzel CJ
    Clin Rheumatol; 2017 Apr; 36(4):895-901. PubMed ID: 28271234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review.
    Xie Y; Liu Y
    Clin Exp Dermatol; 2022 Sep; 47(9):1627-1635. PubMed ID: 35466472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors.
    Kirkham B; Sesin C; Gellett AM; Sprabery AT; Lin CY; Turkiewicz A
    Rheumatology (Oxford); 2021 Sep; 60(9):4367-4372. PubMed ID: 33479721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gender differences in biologic treatment outcomes-a study of 1750 patients with psoriatic arthritis using Danish Health Care Registers.
    Højgaard P; Ballegaard C; Cordtz R; Zobbe K; Clausen M; Glintborg B; Kristensen LE; Dreyer L
    Rheumatology (Oxford); 2018 Sep; 57(9):1651-1660. PubMed ID: 29893926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
    Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A
    Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.
    Kristensen LE; Lie E; Jacobsson LT; Christensen R; Mease PJ; Bliddal H; Geborek P
    J Rheumatol; 2016 Jan; 43(1):81-7. PubMed ID: 26628604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study.
    Cordtz RL; Askling J; Delcoigne B; Smedby KE; Baecklund E; Ballegaard C; Isomäki P; Aaltonen K; Gudbjornsson B; Love TJ; Provan SA; Michelsen B; Sexton J; Dreyer L; Hellgren K
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36564101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study.
    Kavanaugh A; McInnes IB; Mease PJ; Hall S; Chinoy H; Kivitz AJ; Wang Z; Mpofu S
    J Rheumatol; 2016 Sep; 43(9):1713-7. PubMed ID: 27307536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity.
    Harrold LR; Stolshek BS; Rebello S; Collier DH; Mutebi A; Wade SW; Malley W; Greenberg JD; Etzel CJ
    J Rheumatol; 2018 Jan; 45(1):78-82. PubMed ID: 28966209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients.
    Kalyoncu U; Bayindir Ö; Ferhat Öksüz M; Doğru A; Kimyon G; Tarhan EF; Erden A; Yavuz Ş; Can M; Çetin GY; Kılıç L; Küçükşahin O; Omma A; Ozisler C; Solmaz D; Bozkirli ED; Akyol L; Pehlevan SM; Gunal EK; Arslan F; Yılmazer B; Atakan N; Aydın SZ;
    Rheumatology (Oxford); 2017 Feb; 56(2):279-286. PubMed ID: 27794533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How much is fatigue explained by standard clinical characteristics of disease activity in patients with inflammatory arthritis? A longitudinal study.
    Minnock P; McKee G; Bresnihan B; FitzGerald O; Veale DJ
    Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1597-603. PubMed ID: 24966144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis.
    Stober C; Ye W; Guruparan T; Htut E; Clunie G; Jadon D
    Rheumatology (Oxford); 2018 Jan; 57(1):158-163. PubMed ID: 29077973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.
    Hellgren K; Smedby KE; Backlin C; Sundstrom C; Feltelius N; Eriksson JK; Baecklund E; Askling J
    Arthritis Rheumatol; 2014 May; 66(5):1282-90. PubMed ID: 24782185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
    Mease PJ; Woolley JM; Singh A; Tsuji W; Dunn M; Chiou CF
    J Rheumatol; 2010 Jun; 37(6):1221-7. PubMed ID: 20395648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuropathic-like pain in psoriatic arthritis: evidence of abnormal pain processing.
    Ramjeeawon A; Choy E
    Clin Rheumatol; 2019 Nov; 38(11):3153-3159. PubMed ID: 31325065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.